Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Array Achieves Amgen Clinical Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Array Achieves Amgen Clinical Milestone

Triggers $8.5 million payment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Array BioPharma, Inc. has achieved an $8.5 million milestone in its collaboration with Amgen for the worldwide development of the small-molecule glucokinase activator (GKA) program, including AMG 151. The milestone was achieved after reaching predefined patient enrollment in a Phase IIa trial.
 
The Phase IIa trial is a randomized, double-blind, placebo-controlled study of AMG 151 in combination with metformin in patients with type 2 diabetes. The primary endpoint is change in fasting plasma glucose levels from baseline to end of treatment.
 
Under the agreement, Array received an upfront fee of $60 million and is entitled to receive as much as $658 million in additional milestone payments if all clinical and commercialization milestones for AMG 151 and at least one backup compound are achieved. Array will also receive royalties on sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics